Integrated Microfluidic LC-MS - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Integrated Microfluidic LC-MS
The authors describe a new microfluidic-based workflow that integrates and automates glycan cleaveage, purification, and chromatographic separation onto a microfluidic liquid chromatography–mass spectrometry chip for MS detection.

Pharmaceutical Technology
Volume 34, pp. s32-s39

Traditional N-glycan characterization methods

Various methods are used to characterize N-glycans. Figure 1 summarizes those most commonly used. Most require multiple steps and a day or more to complete. All typically follow the same basic process as follows:

  • Release of glycans from glycoproteins
  • Separation of glycans from the deglycosylated protein
  • Analysis (separation, detection, identification, and quantification) of glycans with or without derivatization.

Enzymatic digestion with PNGase F ((peptide-N4-(N-acetyl-β-D-glucosaminy-I)) asparagine amidase F; EC is commonly used to release glycans from glycoproteins. PNGase F is an amidase that cleaves the amide bond between the glycosylation-site asparagine and the innermost N-acetyl-β-D-glucosamine residue of N-glycans. It has a wide specificity, releasing all major classes of N-glycans found on mammalian glycoproteins. As shown in Figure 1, this method of deglycosylation involves long incubation times of 3 to 20 h, a significant component of the overall analysis time.

After releasing the glycans, the next step is to separate and recover them from the deglycosylated protein. This step is commonly done using reverse-phase or graphitized carbon-based solid-phase extraction, ultrafiltration, and precipitation. Centrifugal evaporation is typically needed to concentrate and dry the purified glycans. Depending on the method used, this step can take several hours to complete (see Figure 1).

Various methods are used to separate and detect glycans. Although high pH anion-exchange chromatography (HPAEC), with pulsed amperometric detection (PAD), has been popular because it does not require derivatization (4), it is being replaced by newer methods such as high-performance liquid chromatography (HPLC) and capillary electrophoresis (CE) with fluorescence detection. To improve the separation and enhance detection sensitivity, these methods involve derivatizing free glycans with fluorophore (via reductive amination.) After separation, the glycans' retention time or migration time is measured, and peaks are correlated with standards. Relative quantitation is performed based on the fluorescence of individual peaks (5). For CE analysis, glycans are usually labeled with fluorescent tag APTS (8-aminopyrene-1,3,6-trisulfonic acid.) (6). For HPLC analysis, glycans are typically labeled with a fluorescent label such as 2-aminopyridine (2-AP), anthranilic acid (2-AA), or 2-aminobenzamide (2-AB), and separation is performed using either hydrophilic interaction chromatography (HILIC) or reverse-phase chromatography. Depending on the method used, labeling requires about 1–3 h to complete. Postlabeling cleanup further increases the time requirements needed to complete the analysis.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here